

Oláh Edit

PUBLIKÁCIÓS JEGYZÉK impact faktorral

Idegennyelvű referált közlemények

1. Holczinger, L., Turi, G., Oláh, E., Gál, F.
The role of heterogeneity of tumour cell populations in biological activity and sensitivity to chemotherapeutics.
ACTA MORPH ACAD SCI HUNG 24: 351358, 1976; IF: 0.303
2. Pályi, I., Oláh, E., Sugár, J.
Drug sensitivity studies on cloned cell lines isolated from heteroploid tumour cell populations. I. Doserresponse of cell clones growing in monolayer cultures.
INT J CANCER 19: 859865, 1977; IF: 5.058
3. Oláh, E., Pályi, I., Sugár, J.
Effects of cytostatics on proliferating and stationary cultures of mammalian cells.
EUR J CANCER 14: 895900, 1978; IF: 2.120
4. Weber, G., Kizaki, H., Tzeng, D., Shiotani, T., Oláh, E.
Colon tumor: Enzymology of the neoplastic program.
LIFE SCI 23: 729736, 1978; IF: 3.410
5. Oláh, E., Weber, G.
Giemsa banding karyotype of rat hepatomas of different growth rates.
CANCER RES 39: 17081717, 1979; IF: 3.948
6. Weber, G., Oláh, E., Lui, M.S., Tzeng D.
Biochemical programs and enzyme pattern targeted chemotherapy in cancer cells.
ADV ENZYME REGUL 17: 121, 1979; IF: 0.985
7. Weber, G., Oláh, E., Lui, M.S., Kizaki, H., Tzeng, D., Takeda, E.
Biochemical commitment to replication in cancer cells.
ADV ENZYME REGUL 18: 326, 1980; IF: 1.717
8. Oláh, E., Lui, M.S., Tzeng, D., Weber, G.
Phase and cell cycle specificity of pyrazofurin action.
CANCER RES 40: 28692875, 1980; IF: 4.133
9. Weber, G., Oláh, E., Denton, J.E., Lui, M.S., Takeda, E., Tzeng, D., Ban, J.
Dynamics of modulation of biochemical programs in cancer cells.
ADV ENZYME REGUL 19: 87102, 1981; IF: 2.182
10. Ban, J., Oláh, E., Weber, G.
Action of 1,4dimethyloxyethylamino 1,4dideoxymerythritol (Lycurim) and pyrazofurin on hepatoma 3924A cells in culture.
CANCER TREAT REP 66: 343349, 1982; IF: 1.653
11. Ban, J., Oláh, E., Weber, G.
Antitumor activity of 3,4,5tri-hydroxybenzohydroxamic acid on proliferating and resting hepatoma 3924A cells.
PERIOD BIOL 84: 327331, 1982; IF: 0.313
12. Ban, J., Oláh, E., Weber, G.

- Cytotoxic and cell kinetic effects of 3,4,5-tri-hydroxybenzohydroxamic acid (VF122) in hepatoma 3924A cells.*
CANCER TREAT REP 66: 20712080, 1982; IF: 1.653
13. Oláh, E., Tóth, K., Sugár, J., Hegedüs, L., Somfai-Relle, S.
Effects of some sugar alcohol derivatives on mutation and induction of sister chromatid exchanges.
CANCER RES 43: 45304536, 1983; IF: 3.788
14. Tóth, K., Sugár, J., Oláh, E., Somfai-Relle, S.
Comparative study on the mutagenic and anticancer effect of dibromodulcitol (DBD) and its conversion products.
MED BIOL ENV 11: 49-51, 1983
15. Bartha, E., Oláh, E., Szelényi, J., Bak, M., Sugár, J., Hollán, Zs.
Characterisation of human K562 leukaemia after hemin administration.
ACTA PHYSIOL ACAD SCI HUNG 62: 247-258, 1983; IF: 0.297
16. Lui, M.S., Faderan, M.A., Liepniek, J.J., Natsumeda, Y., Oláh, E., Jayaram, H.N., Weber, G.
Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2 β D-Ribofuranosylthiazole4carboxamide).
J BIOL CHEM 259: 50775082, 1984; IF: 6.118
17. Tóth, K., Oláh, E., Somfai-Relle, S., Sugár, J.
Effect of herbicide 2,4,5-trichlor-4-phenoxyethanol (TCPE) containing dioxin on mutation and induction of sister chromatid exchanges.
CARCINOGENESIS 5: 17251728, 1984; IF: 2.650
18. Oláh, E., Sugár, J., Weber, G.
Enhancement of cytotoxic action of alkylating sugar alcohol derivatives by Pyrazofurin.
CELL TISSUE KINET 17: 301302, 1984; IF: 1.583
19. Oláh, E., Kremmer, T., Boldizsár, M.
Potentiation of antimetabolite action by dibromdulcitol in cell culture.
ADV ENZYME REGUL 24: 155157, 1986; IF: 1.556
20. Ban, J., Oláh, E., van't Riet, B., Weber, G.
Lycurim in combination chemotherapy with 3,4,5-trihydroxybenzohydroxamine acid in vitro.
PERIOD BIOLOGORUM 88: 1924, 1986; IF: 0.297
21. Bartha, E., Oláh, E., Szelényi, J., Hollán, S.R.
Characterization of "fetatype" acetylcholinesterase in hemintreated K562 cell culture.
BLOOD CELLS 12: 647651, 1987; IF: 0.826
22. Sugár, J., Tóth, K., Oláh, E.
Carcinogenicity and genotoxicity of the herbicide 2,4,5 trichlorophenoxyethanol (TCPE) contaminated with dioxin.
ANN NY ACAD SCI 534: 706713, 1988; IF: 0.748
23. Oláh, E., Natsumeda, Y., Köte, Zs., Horányi, M., Szelényi, J., Paulik, E., Kremmer, T., Hollán, S.R., Sugár, J., Weber, G.
Induction of erythroid differentiation in K562 leukemia cells by tiazofurin and modulation of gene expression.
P NATL ACAD SCI USA 85: 65336537, 1988; IF: 10.032
24. Natsumeda, Y., Ikegami, T., Oláh, E., Weber, G.
Significance of purine salvage in circumventing the action of antimetabolites.
CANCER RES 49: 8892, 1989; IF: 4.522

25. Weber, G., Jamayi, Y., Oláh, E., Natsumeda, Y., Jayaram, H.N., Lapis, E., Zhen, W., Prajda, N., Hoffman, R., Tricot, G.J.
Clinical and molecular impact of inhibition of IMP dehydrogenase activity by tiazofurin.
ADV ENZYME REGUL 28: 335356, 1989; IF: 1.809
26. Oláh, E., Ezer, R., Giaretti, W., Eble, J.
Metabolic control of oncogene expression.
BIOCHEM SOC T 18: 7274, 1989; IF: 2.735
27. Oláh, E., Köte, Zs., Natsumeda, Y., Jamayi, Y., Járαι, G, Lapis, E., Financsek, I., Weber, G.
Downregulation of cmyc and cHaras gene expression by tiazofurin in rat hepatoma cells.
CANCER BIOCHEM BIOPHYS 11: 107117, 1990; IF: 0.550
28. Mayer, D., Natsumeda, V., Ikegami, V., Faderan, M., Lui, M.S., Emrani, J., Oláh, E., Weber, G.
Expression of key enzymes of purine and pyrimidine metabolism in a hepatocytederived cell line at different phases of the growth cycle.
J CANCER RES CLIN ONCOL 116: 251258, 1990; IF: 1.153
29. Weber, G., Nagai, M., Prajda, N., Nakamura, H., Szekeres, T., Oláh, E
AZT: A biochemical response modifier of methotrexate and 5'fluoro-uracil cytotoxicity in human ovarian and pancreatic carcinoma cells.
CANCER COMMUN (ONCOLOGY RES) 3: 127-132, 1991; IF1993: 2.412
30. Look, K.Y., Sutton, G.P., Natsumeda, Y., Eble, J.N., Stehman, F.B., Ehrlich, C.E., Oláh, E., Prajda, N., Bösze, P., Eckhardt, S., Weber, G.
Inhibition by tiazofurin of inosine 5-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomas.
GYNECOL ONCOL 47: 66-70, 1992; IF: 1.423
31. Csókay, B., Papp, J., Besznyák, I., Bösze, P., Sárosi, Zs., Tóth, J., Zalay, Zs., Oláh, E.
Oncogene patterns in breast and ovarian carcinomas.
EUR J SURG ONCOL 19: 593-599, 1993
32. Yeh, Y.A., Oláh, E., Wendel, J.J., Sledge, G.W., Weber, G.
Synergistic action of taxol with tiazofurin and methotrexate in human breast cancer cells: schedule dependence.
LIFE SCI 54: 431-435, 1994; IF: 2.500
33. Cornelis, R.S., Neuhausen, S.L., Arason, A., Kelsell, D., Ponder, B.A.J., Johansson, O., Tonin, P., Hamann, U., Lindblom, A., Lalle, P., Longy, M., Oláh, E., Scherneck, S., Bignon, Y.J., Sobol, Y., Chang-Claude, J., Larsson, C., Spurr, N., Borg, A., Barkardottir, R.B., Narod, S., Devilee, P.
Allele loss rates at 17q12-q21 in breast and ovarian tumors from 52 germline BRCA1 mutation carriers.
GENE CHROMOSOME CANCER 13: 203-210, 1995; IF: 4.764
34. Sápi, V., Lukács, G., Sztán, M., Papp, V., Oláh, E.
Contribution of p53 gene alterations to development of metastatic forms of follicular thyroid carcinoma.
DIAGN MOL PATHOL 4: 256-260, 1995; IF: 2.880
35. Singhal, R.L., Yeh, Y.A., Prajda, N., Oláh, E., Sledge, G.W., Weber, G.
Quercetin down-regulates signal transduction in human breast carcinoma cells.
BIOCHEM BIOPH RES CO 208: 425-431, 1995; IF: 3.179
36. Prajda, N., Singhal, V., Yeh, Y.A., Oláh, E., Look, K.Y., Weber, G.
Linkage of reduction in 1-phosphatidylinositol 4-kinase activity and inositol 1,4,5-

- triphosphate concentration in human ovarian carcinoma cells treated with quercetin.*
LIFE SCI 56: 1587-1593, 1995; IF: 2.345
37. J. Papp, B. Csókay, P. Bősze, Zs. Zalay, J. Tóth, B. Ponder, E. Oláh
Allele loss from large regions of chromosome 17 is common only in certain histological subtypes of ovarian carcinomas.
BRIT J CANCER 74: 1592-1597, 1996; IF: 3.666
38. Oláh, E., Csókay, B., Prajda, N., Köte-Járai, Zs., Yeh, Y.A., Weber, G.
Molecular mechanisms in the antiproliferative action of taxol and tiazofurin.
ANTICANCER RES 16: 2469-2478, 1996; IF: 1.049
39. Sztán, M., Besznyák, I., Kovács, V., Tóth, J., Számel, J., Oláh, E.
Lack of correlation between survival and allele loss on chromosome 7q31-32 in primary breast cancer.
PATHOL ONCOL RES 2: 48-51, 1996.
40. Van der Looij, M., Eid, H., Bak, M., Bodrogi, I., Oláh, E.
Allele loss of tumor suppressor genes on chromosome 17 in human testicular germ cell tumours.
INT J ONCOL 9: 1087-1090, 1996; IF: 1.125
41. H., Eid, I., Bodrogi, B., Csókay, E., Oláh, M., Bak
Multidrug resistance of testis cancers. The study of clinical relevance of P-glycoprotein expression.
ANTICANCER RES 16: 3447-3452, 1996; IF: 1.049
42. Devilee, P., Hermans, J., Eyfjörd, J., Borresen, A.L., Lindereau, R., Sobol, V., Borg, V., Cleton-Jansen, V., Oláh, E., Steel, M., Scherneck, S., Hamann, V., Peterlin, B., Caligo, M.A., Bignon, Y.J., Maugard-Louboutin, C. & The Breast Cancer Somatic Genetics Consortium
Loss of heterozygosity at 7q31-q32 in breast cancer: Results from an international collaborative Study Group.
GENE CHROMOSOME CANC 18: 193-199, 1997; IF: 4.653
43. Csókay, B., Prajda, N., Weber, G., Oláh, E.
Molecular mechanisms in the antiproliferative action of quercetin.
LIFE SCI 60: 2157-2163, 1997; IF: 2.275
44. Ramus, S., Friedman, L.S., Gayther, S.A., Ponder, B.A.J., Bobrow, L., van der Looij, M., Papp, J., Oláh, E.
A breast/ovarian cancer patient with germline mutations in both the BRCA1 and BRCA2 genes.
NAT GENET 15: 14-15, 1997; IF: 38.854
45. Weber, G., Shen, F., Prajda, N., Yang, H., Li, W., Yeh, Y.A., Csókay, B., Oláh, E., Look, K.Y.
Regulation of the signal transduction program by drugs.
ADV ENZYME REGUL 37: 35-55, 1997; IF: 1.756
46. Ramus, S., Járai-Köte, Zs., Friedman, V., van der Looij, M., Gayther, S.A., Csókay, B., Ponder, B.A.J., Oláh, E.
Analysis of BRCA1 and BRCA2 mutations in Hungarian breast and/or ovarian cancer families.
AM J HUM GENET 60: 1242-1246, 1997; IF: 10.244
47. Sztán, M., Pápai, Zs., Szendrői, M., van der Looij, M., Oláh, E.
Allelic losses from chromosome 17 in human osteosarcomas.
PATHOL ONCOL RES 3: 115-120, 1997
48. Pápai, Zs., Féja, C.N., Hanna, E., Sztán, M., Oláh, E., Szendrői, M.

- p53 overexpression as an indicator of overall survival and response to treatment in osteosarcomas.*
PATHOL ONCOL RES 3: 15-19, 1997
49. Eid, H., van der Looij, M., Institoris, E., Géczi, L., Bodrogi, I., Oláh, E., Bak, M.
Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer?
ANTICANCER RES 17: 2663-2670, 1997; IF: 1.045
50. Phelan, C.M., Borg, A., Cuny, M., Crichton, N., Baldersson, T., Andersen, T., Caligo, M.A., Lidereau, R., Lindblom, A., Seitz, S., Kelsell, D., Hamann, U., Rio, P., Thorlacius, S., Papp, J., Oláh, E., Ponder, B., Scherneck, Y.J., Barkardottir, R., Borresen-Dale, A., Eyfjörd, J., Theillet, Ch., Thompson, A.M., Devilee, P., Larsson C.
Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters.
CANCER RES 58: 1008-1012, 1998; IF: 8.370
51. Neuhausen, S., Godwin, A., Gershoni-Baruch, R., Schubert, E., Garber, J., Stoppa-Lyonnet, D., Oláh, E., Csókay, B., Serova, O., Lalloo, F., Stratton, M., Offit, K., Boyd, J., Caligo, A., Scott, Schofield, A., Teugels, E., Cannon-Albright, L., Bishop, T., Benitez, J., King, M.-C., Ponder, B., Weber, B., Devilee, P., Borg, A., Narod, S., Goldgar, D.
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study.
AM J HUM GENET 62: 1381-1388, 1998; IF: 10.869
52. Launonen, V., Laake, K., Huusko, P., Borresen-Dale, A-L., Beckmann, M.W., Niederacher, D., Geirsdottir, E.K., Gudmundsson, V., Barkardóttir, R.B., Rio, P., Bignon, Y-J., Seitz, S., Scherneck, S., Bièche, I., Champéne, M-H., Lidereau, R., Birnbaum, D., White, G., Varley, J., Sztan, M., Olah, E., Osorio, A., Benitez, J., Spurr, N., Velikonja, N., Peterlin, B., Borg, A., Cleton-Jansen, M-C., Devilee, P., Bloigu, R., Winqvist, R.
European consortium study on LOH at 11q23.3 in 766 breast cancer patients: relation to clinical variables.
BRIT J CANCER 80: 879-882, 1999; IF: 3.282
53. Laake, K., Launonen, V., Niederacher, D., Gudlaugsdottir, S., Seitz, S., Rio, P., Chaméme, M-H., Bieche, I., Birnbaum, D., White, G., Sztan, M., Sever, N., Plummer, Osorio, A., Broeks, A., Huusko, P., Spurr, N., Borg, A., Cleton-Jansen, A-M., van □t Veer, L., Benitez, J., Casey, G., Peterlin, B., Olah, E., Varley, J., Bignon, Y-J., Scherneck, S., Sigurdardottir, V., Lidereau, R., Eyfjord, J., Beckmann, M.W., Winqvist, R., Skovlund, E., Borsen-Dale, A-L.
Loss of heterozygosity at 11q23.1 and survival in breast cancer: result of a large European study.
GENE CHROMOSOME CANCER 25: 212-221, 1999; IF: 4.902
54. Csókay, B., Udvarhelyi, N., Sulyok, Z., Besznyák, I., Ramus, S., Ponder, B., Oláh, E.
High frequency of germline BRCA2 mutations among Hungarian male breast cancer patients without family history.
CANCER RES 59 (5): 995-998, 1999; IF: 8.614
55. Oláh, E.
Molecular cancer genetics in Eastern and Central Europe.
DIS MARKERS 15: 75-77, 1999; IF: 0.524
56. Morrison, P.J., Steel, C.M., Vasen, H.A., Eccles, D., Evans, D.G., Moller, P., Hodgson, S., Stoppa-Lyonnet, D., Chang-Claude, J., Caligo, M., Olah, E., Haites, N.E., Nevin, N.C.
Insurance implications for individuals with a high risk of breast and ovarian cancer in Europe.
DIS MARKERS 15: 159-165, 1999; IF: 0.524

57. Van der Looij, M., Cleaton-Jansen, A-M., van Eijk, M., van Vliet, M., Kuipers-Dijkshorn, N., Oláh, E., Cornelisse, C.J., Devilee, P.
A sporadic breast tumor with a somatically acquired complex genomic rearrangement in BRCA1.
GENE CHROMOSOME CANC 27: 295-302, 2000; IF: 4.534
58. Csókay, B., Tihomirova, L., Stengrevics, A., Sinicka, O., Oláh, E.
Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia.
HUM MUTAT 14 (1): 92, 1999. Mutation in Brief #258 Online.; IF: 2.642
59. Van der Looij, M., Wysocka, B., Brozek, I., Limon, J., Oláh, E.
Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland.
HUM MUTAT 2000. Mutation in Brief #320 Online.; IF: 2.642
60. Papp, J., Raicevic, L., Milasin, J., Dimitrijevic, B., Radulovic, S., Oláh, E.
Germline mutation analysis of BRCA1 and BRCA2 genes in Yugoslav breast/ovarian cancer families.
ONCOL REP 6 (6): 1435-1438, 1999; IF: 0.659
61. Van der Looij, V, Szabo, C.I., Besznyák, I., Liszka, G., Csókay, B., Pulay, T., Devilee, P., King, M-C., Oláh, E.
Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary.
INT J CANCER 86: 737-740, 2000; IF: 3.918
62. Orbán, T., Csókay, B., Oláh, E.
Sequence alterations can mask the presence of each other when screening with SSCP or HA: BRCA genes as examples.
BIOTECHNIQUES 29: 94-98, 2000; IF: 1.756
63. The BRCA1 exon 13 duplication screening group (Mazoyer, S., Leary, J., Kirk, J., Fleischmann, E, Wagner, T, Claes, K., Messiaen, L., Foulkes, W., Desrochers, M., Simard, J., Phelan, C.M., Ponder, B.A.P., Robinson, M., Taylor, G.R., Bishop, T., Solomon, E., Catteau, A., Cohen, B., Steel, M., Collins, N., Stratton, M., van der Looij, M., Oláh E., Miller, N.J., Barton, D.E., Sverdlov, R.S., Friedman, E., Radice, P., Montagna, M., Sensi, E., Caligo, M., van Eijk, R., Devilee, P., van der Lujit, R., Heimdal, K., Moller, P., Borg, Á., Diez, O., Cortes, J., Domenech, M., Baiget, M., Osorio, A., Benitez, J., Maillet, P., Sappino, P., Özdag, H., Özcelik, T., Ozturk, M., Rohlf, E.M., Boyd, J., Mc-Dermott, D., Offit, K., Unger, M., Nathanson, K., Weber, B.L., Sellers, T.A., Couch, F.J., Neuhausen, S.)
The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations.
AM J HUM GENET 67: 207-212, 2000; IF: 10.351
64. Orbán, T., Oláh, E.
Expression profiles of BRCA1 splice variants in asynchronous and in G1/2 synchronized tumor cell lines.
BIOCHEM BIOPH RES CO 280: 32-38, 2001; IF: 2.946
65. Horváth, C.F., Bocsi, J., Rásó, E., Orbán, T.I., Oláh, E., Tímár, J. Ladányi, A.
Constitutive intracellular expression and activation-induced cell surface upregulation of CD44v3 in human T-lymphocytes.
EUR J IMMUNOL 31: 600-608, 2001; IF: 4.990
66. Van der Looij, M., Papp, J., Sztán, M., Pulay, T., Elfadil, I., Besznyák, I., Tóth, J., Devilee, P., Oláh, E.
Allelic imbalance and microsatellite instability in BRCA1 associated breast and ovarian

tumors.

INT J ONCOL 18: 775-780, 2001; IF: 2.330

67. Thompson, D., Szabo, C.I., Mangion, J., Oldenburg, R.A., Odefrey, F., Seal, S., Barfoot, R., Kroeze-Jansema, K., Teare, D., Rahman, N., Renard, H., KconFab Consortium, Mann, G., Hopper, J.L., Buys, S., Andrulis, I.A., Senie, R., Daly, M.B., West, D., Ostrander, E.A., Offit, K., Peretz, T., Osorio, A., Benitez, J., Nathanson, K.L., Sinilnikova, O.M., Oláh, E., Bignon, Y.-J., Ruiz, P., Badzioch, M.D., Vasen, H.F.A., Futreal, A.P., Phelan, C.M., Narod, S.A., Lynch, H.T., Ponder, B.A.J., Eeles, R.A., Meijers-Heijboer, H., Stoppa-Lyonnet, D., Couch, F.J., Eccles, D.M., Evans, G., Chang-Claude, J., Lenoir, G., Weber, B., Devilee, P., Easton, D.F., Goldgar, D.E.
Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium.
P NATL ACAD SCI USA. 99:2 827-831, 2002; IF: 10.700
68. Forgács, É., Zöchbauer-Müller, S., Oláh, E., Minna, J.D.
Molecular genetic abnormalities in the pathogenesis of human lung cancer.
PATHOL ONCOL RES 7: 6-13, 2001
69. Orbán, T.I., Oláh, E.
Purifying selection on silent sites □ a constraint from splicing regulation?
TRENDS GENET 17: 252-253, 2001; IF: 12.417
70. Thompson D., Easton D. F., The Breast Cancer Linkage Consortium (McGuffog, L.M., Weber, B., Gad, S., Stoppa-Lyonnet, D., Korn, V., Kroiss, R., Langbauer, G., Muhr, D., Wagner, T., Goldgar, D., Lenoir, G., Lynch, H.T., Narod, S., Sinilnikova, O., Gayther, S., Ponder, B., Taylor, A., Klijn, J.G.M., Meijers-Heijhoher, H., Olah E., Sobol, H., Eisinger, F., Borg, A., Johannsson, O., Loman, N., Olsson, H., Chang-Clauder, J., Hamann, U., Weber, B.H.F., Arver, B., Lindblom, A., Eeles, R., Ford, D., Peto, J., Stratton, M., Cannon-Albright, L., Neuhausen, S.L., Eerola, H., Nevanlinna, H., Bignon, Y., Manoukian, S., Pasini, B., Pierotti, M.A., Radice, P., Futreal, A., Cornelisse, C.J., Devilee, P., Vasen, H., Maugard, C.M., Campbell, J., McCleish, L., Stell, M., Scherneck, S., Seitz, S., Bishop, D.T., Crockford, G., Benitez, J., Osorio, A., Narod, S., Beckmann, M.W., Kuschel, B., Haites, N., Schofield, A., Evans, G.)
Cancer incidence in BRCA1 mutation carriers.
J NATL CANCER INST 94: 1358-1365., 2002; IF: 14.500
71. Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, A., Pasini, B., Radice, P., Manoukian, S., Eccles, D. M., Tang, N., Olah, E., Anton-Culver, H., Warner, E., Lubinski, J., Gronwald, V., Gorski, B., Tulinius, H., Thorlacius, S., Eerola, Nevanlinna, H., Syrjakoski, K., Kallioniemi, O.-P., Thompson, D., Evans, C., Peto, J., Lalloo, F., Evans, D.G., Easton, D.F.
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history, a combined analysis of 22 studies.
AM J HUM GENET 72(5) 1117-1130, 2003; IF2002: 10.649
72. Weber G., Shen F., Orban T. I., Kökény Sz., Oláh E.
Targeting signal transduction.
ADV ENZYME REGULAT 43: 47-56, 2003.; IF2002: 2.548
73. Orbán T. I., Oláh E.
Emerging roles of BRCA1 alternative splicing.
J CLIN PATHOL: MOL PATHOL □ Invited Review (nyomdában) 2003; IF2002: 2.549
74. Looijenga L.H.J., de Leeuw H., van Oorschot M., van Gurp R., Stoop H., Gillis A.J., de Gouveia de Braza CA, Weber R.F.A., van Dijk T., von Lindren M., Geczi L., Oláh E., Nesland J.M., Fossa S.D., Oosthuis J.W.

Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ cell tumors.

BRIT J CANCER 2003 (közlésre elfogadva)

75. Rapley EA, Hockley S, Warren W, Johnson L, Huddart R, Crockford G, Forman D, Leahy M, Oliver T, Tucker K, Friedlander M, Phillips K, Hogg D, Jewett M, Lohynska R, Daugard G, Richard S, Heidenreich A, Geczy L, Bodrogi I, Oláh E, Ormiston W, Daly P, Looijenga LHJ, Guilford P, Aass N, Heimdal K, Tjulandin SA, Liubcenko L, Stoll H, Weber W, Einhorn L, Weber B, McMaster M, Greene MH, Bishop DT, Easton D, Stratton MR
Somatic mutations of KIT in familial testicular germ cell tumors
BRIT J CANCER 2003 (közlésre elfogadva)

Magyar nyelvű közlemények

1. Oláh E., Pokorny É., Somosy Z., Sugár J
A dibrómdulcit hatása kínai hörcsög sejtek túlélésére, nukleáris tartalmára és a G1 fázisú sejtek ultrastruktúrájára.
MAGYAR ONKOLÓGIA 18: 144-152, 1974.
2. Oláh E., Pályi I., Pokorny É., Sugár J.
Citosztatikumok hatása proliferáló és nem proliferáló kínai hörcsög sejttenyésztetre.
MAGYAR ONKOLÓGIA 22: 237-244, 1978.
3. Bak M., Oláh E., Gaál D., Pokorny É., Sugár J.
Humán bronchus carcinoma xenograft biológiai és morfológiai vizsgálata.
MORPH. ÉS IG. ORV. SZEMLE. 24: 171-179, 1984.
4. Bak M., Oláh E., Sugár J.
Humán bronchus carcinoma xenograft növekedése és szövettani vizsgálata.
PNEUMONOLOGIA HUNG. 37: 225-228, 1984.
5. Tóth K., Oláh E.
Dioxinnal szennyezett 2,4,5-triklórfenoxietanol (herbicide) karcinogenitása és genotoxicitása.
MAGYAR ONKOLÓGIA 29: 264-270, 1985.
6. Oláh E.
Onkogén kaszkád.
MAGYAR ONKOLÓGIA 32: 145-153, 1988.
7. Oláh E.
Onkogének, tumor-szuppresszor gének (anti-onkogének) szerepe a daganatok patogenezisében.
MAGYAR PEDIÁTER 25: 133-139, 1991.
8. Bak M., Hanna Eid, B.Csóky, I.Bodrogi, E.Oláh
A hererákok multidrog rezisztenciája (A P-glycoprotein és a MDR1 gén expresszió vizsgálata és klinikai összefüggése).
ORVOSI HETILAP 136: (1) 19-25, 1995.
9. Bősze P, Orosz-Tóth M, Oláh E., Artner A.
Hüvelyrák kialakulása egy családi petefészekrák terheltség miatt veszélyeztetett asszonyban.
ORVOSI HETILAP 136 (50) 2731-2732, 1995.
10. Oláh E., Csóky B., Járai-Köte Zs., M. van der Looij, Papp J., Sztán M.
Öröklődő BRCA1 mutációk hazai emlő/petefészekrákos családokban.
MAGYAR ONKOLÓGIA 41: 69-73, 1997.
11. Oláh E

Szemléletváltás a daganatkutatásban □ lehetőségek a rákprevencióban.

MAGYAR ONKOLÓGIA 42: 50-51, 1998.

12.E.Oláh

Örökletes daganatos megbetegedések (örökölt rákhajlam és rákszindrómák).

ORVOSI HETILAP 140 (9): 451-466, 1999. (Markusovszky díjas közlemény)

13.Oláh, E.

A DNS molekulától a betegágyig: a molekuláris medicina hídja.

MAGYAR TUDOMÁNY 2003/5:582-592

14.Oláh, E.

Molekuláris onkogenetika, onkogenomika. Krompecher emlékelőadás.

MAGYAR ONKOLÓGIA 46: 287-290, 2002.

15.Oláh, E

Molekuláris genetikai szűrővizsgálatok javallatai és korlátai az onkológiában.- Review.

FOCUS MEDICINAE 2003 (közlés alatt)

Könyvfejezetek

1. Pályi, I., Oláh, E., Pályi, V.

Effect of Dibromodulcitol on life-cycle of cells in culture.

In: ADVANCES IN ANTIMICROBIAL CHEMOTHERAPY, Urban und Schwarzenberg (München, Berlin, Wien), 2: 423-426, 1972

2. Sugár, J., Csuka, O., Oláh, E.

Studies on polysaccharide coat of tumour cells.

In: CHARACTERIZATION OF HUMAN TUMOURS, Eds. W.Davies and C.Maltoni, 5: 304-308, 1973

3. Pályi, I., Oláh, E.

Cytomorphology and sensitivity of cell clones to anticancer drugs.

In: INHIBITION OF GROWTH AND PHARMACOLOGY DIRECTED FOR REGULATION OF CELL PROLIFERATION IV, Eds. F.Hernádi and G.Szabó, p.307-316, 1975.

4. Weber, G., Oláh, E., Lui, M.S., Tzeng, D.

Enzymepatterntargeted chemotherapy and mechanism of pyrazofurin action.

In: ADVANCES IN MEDICAL ONCOLOGY, RESEARCH AND EDUCATION, Ed. Fox, B. W. (Pergamon Press: Oxford, New York), Vol. 5. Basis for Cancer Therapy. 1: 151166, 1979

5. Oláh, E., Sugár, J., Tóth, K.

Mutagenicity of antitumor sugar alcohol derivatives.

In: DRUGS IN CANCER CHEMOTHERAPY, Eds. Aiginger, P. and Seeber, S. p.69, 1983

6. Oláh, E.

Biochemistry of cycling and resting cancer cells.

In: PROGRESS IN CLINICAL AND BIOLOGICAL RESEARCH Eds. Mirand, E.H., W.B. and Mihich, E., (A.R. Liss Inc.: New York, Vol. 132C. Biology of Cancer (2), p. 179188, 1983

7. Ban, J., Oláh, E., Weber, G.

Synergistic interaction of an alkylating agent (Lycurim) and an antimetabolite (Pyrazofurin) on hepatoma 3924A cells in culture.

In: THE CONTROL OF TUMOUR GROWTH AND ITS BIOLOGICAL BASES, Eds. Davies, W.M. and Tanneberger, S., (Akad. Verlag: Berlin), 189193, 1983

8. Sugár, J., Csuka, O., Pályi, I., Oláh, E.
Role of some biological parameters in drug sensitivity and resistance of tumour cells.
In: THE CONTROL OF TUMOUR GROWTH AND ITS BIOLOGICAL BASES. Eds. Davies, W.M. and Tanneberger, S. (Akad. Verlag: Berlin) p.342348, 1983
9. Oláh, E.
Kinetic classification of some sugar alcohol derivatives and induction of sister chromatid exchanges.
In: CMEA CHEMOTHERAPY SYMPOSIUM Eds. S.Eckhardt, S.Kerpel-Frónius (Akadémiai Kiadó: Budapest), p. 343-352, 1985
10. Oláh, E.
Pattern of oncogene expression in hepatoma cells.
In: LIVER CELL CARCINOMA Eds. Bannasch, P.K. and Keppler, D. (Kluwer Academic Publ: Dordrecht, Boston, London), p. 423436, 1989
11. Oláh E
A sejtproliferáció szabályozási zavarai.
In: AZ ONKOLÓGIA ALAPJAI, Szerk. Gomba Sz., Ádány R., Kásler M., Ember I., Kopper L., Thurzó L. (Medicina Kiadó: Budapest) 1:14-20, 1997.
12. Oláh E.
Örökletes emlőrákok genetikája és molekuláris diagnosztikája.
In: AZ EMLŐRÁK AKTUÁLIS KÉRDÉSEI, Szerk. Tóth J. és Péter I. (Springer Orvosi Kiadó Kft., Budapest), p.115-125, 2002
13. Oláh E.
A rák kialakulása.
In: TABULARIA ONKOLOGIAE, szerk. Eckhardt S./ Makara M. (Melánia Kiadó: Budapest), p. 1-5, 2002

Referált folyóiratban megjelent absztraktok

1. E.Oláh, D.Tzeng, H.Kizaki, G.Weber
Changes in the enzymatic programs of proliferating and resting hepatoma 3924A cultures.
CELL TISSUE KINET 13: 208, 1980
2. E.Oláh, J.E.Denton, M.S.Lui, E.Takeda, J.Ban, G.Weber
Kinetic and metabolic alterations of hepatoma 3924A cells during the resting proliferating/resting phase transition.
CELL TISSUE KINET 14: 680, 1981
3. E.Oláh
Drug induced modulation of oncogene expression.
CELL PROLIFERAT 22: 151, 1989
4. E.Oláh, R.Ezer, M.Bak, W.Giaretta
Control of gene expression in druginduced differentiation.
CELL PROLIFERAT 23: 358, 1990
5. E.Oláh, R.Ezer, Zs.Köte
Metabolic and molecular mechanisms mediating expression of differentiated phenotype.
J CANCER RES CLIN ONCOL 116: 1026, 1990
6. E.Oláh
Molecular and cellular basis of drug resistance to tiazofurin (TR), an inducer of cancer cell differentiation.
EUR J CANCER 27: 43, 1991

7. E.Oláh, B.Csóky, J.Papp, M.Bak, N.Prajda, S.Eckhardt
Metabolic targeting -molecular changes in cancer chemotherapy.
CELL PROLIFERAT 25: 468, 1992
8. Zs.Járai-Köte, A.H.M.Burghes, E.Oláh
Coincident PCR: a method for selective isolation of candidate tumor suppressor gene.
CELL PROLIFERAT 25: 467, 1992
9. E.Oláh, B.Csóky, J.Papp
Modulation of gene expression through inhibiting guanylate metabolism.
BIOMED PHARMACOTHER 46: 298, 1992
10. J.Papp, B.Csóky, I.Számel, I.Besznyák, Zs.Zalay, J.Tóth, P.Bösze, E.Oláh
Molecular markers of ovarian and breast carcinomas.
CELL PROLIFERAT 25: 569, 1992
11. E.Oláh, J.Papp, B.Csóky
Pattern and modulation of oncogene abnormalities in ovarian cancer.
PAM ASS CANC RES 34:221, 1993
12. J.Papp, M.Sztán, E.Oláh
Involvement of BRCA1 in development of ovarian and thyroid malignancies.
CELL PROLIFERAT 28: 183, 1995
13. B.Csóky, Zs.Járai-Köte, M. van der Looij, N.Prajda, G.Weber, E.Oláh
Pleiotropic induction of apoptosis and differentiation by taxol and tiazofurin.
CELL PROLIFERAT 28: 202, 1995
14. E.Oláh, M. van der Looij, Zs.Járai-Köte, M.Sztán, J.Papp, B.Csóky
BRCA1 and other regulatory genes in the proliferation of human breast cancer cells.
CELL PROLIFERAT 29: 358, 1996
15. E.Oláh, J.Papp, M.Sztán, B.Csóky, M. van der Looij
Frequent deletion of the BRCA1 region in human malignancies.
BRIT J CANC 73: 46, 1996
16. M. van der Looij, H.N.Eid, M.Bak, E.Oláh
No involvement of the BRCA1 region in testicular germ cell tumors.
BRIT J CANC 73: 83, 1996
17. E.Rásó, E.Oláh, Zs.Járai-Köte, K.Lapis
Action of tiazofurin on human and rat Wilms tumor grafts.
ANTICANCER RES 16: 1810, 1996
18. K.Lapis, E.Rásó, J.Bocsi, J.Tóvári, I.Bartha, E.Oláh, Zs.Járai-Köte, J.Timár
Antiinvasive and antimetastatic effect of tiazofurin on human tumors.
ANTICANCER RES 16: 1809, 1996
19. S.J.Ramus, Zs.Járai-Köte, S.Gayther, L.Friedman, E.Oláh, BAJ.Ponder
Analysis of BRCA1 and BRCA2 mutations in individuals from 43 Hungarian families with a history of breast and/or ovarian cancer.
J MED GENET 33: 1996
20. E.Oláh, G.Németh, J.Papp
BRCA1 and other chromosome 17 genes in pathogenesis of multiple primary cancers.
PAM ASSOC CANC RES 38: 168, 1997
21. C.I.Szabo, M.van der Looij, J.Papp, I.Besznyák, M-C.King, E.Oláh
Prevalence of BRCA1 and BRCA2 mutations in a Hungarian hospital-based series of incident breast and ovarian cancer cases.

- P AM ASSOC CANC RES 39: 475, 1998
- 22.M.van der Looij, C.I.Szabo, T.Orbán, I.Besznyák, G.Liszka, M-C.King, E.Oláh
Founder BRCA1 and BRCA2 mutations in Hungarian women with incident breast or ovarian carcinoma: update of a hospital-based study.
EUR J GYNEC ONCOL 20: 105, 1999
- 23.E.Oláh, B.Csóky, J.Papp, M.van der Looij, L.Tihomirova, L.Raicevic, J.Jassem
BRCA1 and BRCA2 mutation patterns with strong founder effects in Central and East Europe.
P AM ASSOC CANC RES 40: 467, 1999
- 24.T.I. Orbán, E. Oláh
Expression of different BRCA1 splice variants in different cell lines.
P AM ASSOC CANC RES 40: 658, 2000
- 25.Pharoah, IP, A. Antoniou, H. Risch, S. Narod, J. Hopper, N. Loman, H. Olsson, O. Johansson, A. Borg, B. Pasini, P. Radici, D. Eccles, N. Tang, E. Oláh, H. Anton-Culver, J. Eyfjord, D.G. Evans, C. Evans, J. Peto, D. Easton & BRCA1/2 Population Studies Collaborative Group
Average risks of breast and ovarian cancer in women who carry a BRCA1 or BRCA2 mutation: a preliminary analysis of pooled family data from unselected case series.
AM J HUM GENET 69 (4): 425 Suppl 2001
- 26.J.Papp, I.Köves, S.Ottó, E.Oláh
Germline APC mutation spectrum in Hungarian FAP families.
REV ONCOL 4 (1): 125, 2002
- 27.T.I.Orbán, E.Oláh, G.Weber
Ribavirin (Riba) is antiproliferative and oncolytic; it down-regulates c-myc expression and signal transduction, causes apoptosis and induced differentiation.
P AM ASSOC CANC RES 43: 967, 2002
- 28.T. I. Orbán, E. Oláh
Expression profiles of predominant BRCA1 splice variants in normal breast, breast tumours and leukocytes of breast cancer patients.
CELL PROLIFERAT 35(5): 305-306, 2002
- 29.J. Papp, I. Köves, S. Ottó, E. Oláh
Germline APC mutation spectrum in Hungarian FAP families.
CELL PROLIFERAT., 35(5): 307, 2002
- 30.T.I.Orbán, E.Oláh
Expression profiles of predominant BRCA1 splice variants in normal breast, breast tumours and leukocytes of breast cancer patients.
P AM ASSOC CANC RES 44: 999, 2003 (AACR-Avon díjat nyert abstract).